Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22501754 | 0.87 | AR (0.69) | ARALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL29402764 | 0.87 | AR (0.69) | ARALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL1771033 | 0.83 | AR (0.81) | ARLMNAALDH1A1HPGDHSD17B10 | |
| SCHEMBL1773189 | 0.83 | AR (1.00) | AR | |
| SCHEMBL1771931 | 0.82 | AR (1.00) | AR | |
| SCHEMBL7023082 | 0.77 | AR (0.57) | ARALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL13210451 | 0.77 | AR (1.00) | AR | |
| SCHEMBL2056350 | 0.75 | LMNA (0.59) | ARLMNAALDH1A1HPGDHSD17B10 | |
| SCHEMBL11468572 | 0.74 | LMNA (0.62) | ARLMNAALDH1A1HPGDHSD17B10 | |
| SCHEMBL9724162 | 0.73 | LMNA (0.67) | ARLMNAALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | claimed |
| US-6566372-B1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer | LIGAND PHARMACEUTICALS INCORPORATED | 2003-05-20 | — | — | US | claimed |
| JP-2003508387-A | — | — | 2003-03-04 | — | — | JP | claimed |
| EP-1212303-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | claimed |
| WO-2001016108-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | claimed |
| US-20110112084-A9 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2011-05-12 | — | — | US | disclosed |
| US-20100204216-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-beta PROTEIN ACCUMULATION | SUMMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-08-12 | — | — | US | disclosed |
| EP-2199284-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING ACCUMULATION OF AMYLOID- BETA PROTEIN | Sumitomo Chemical Company, Limited (JP) | 2010-06-23 | — | — | EP | disclosed |
| US-7696246-B2 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-04-13 | — | — | US | disclosed |
| US-20100069379-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2010-03-18 | — | — | US | disclosed |
| US-20050288350-A1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer; 6-(bis-2,2,2-Trifluoroethyl)amino-4-trifluoromethylcoumarin | LIGAND PHARMACEUTICALS, INC. | 2005-12-29 | — | — | US | disclosed |
| US-6964973-B2 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-11-15 | — | — | US | disclosed |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6566372-B1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer | LIGAND PHARMACEUTICALS INCORPORATED | 2003-05-20 | — | — | US | disclosed |
| EP-1212303-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016108-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204216-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-beta PROTEIN ACCUMULATION | APP, PSEN1, IAPP | AR 3600/4885LMNA 993/4885ALDH1A1 3632/4885 |
| US-20100069379-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | AR, NR5A1, PGR | AR 1/4885LMNA 2745/4885ALDH1A1 2131/4885 |
| US-20110112084-A9 | Bicyclic androgen and progesterone receptor modulator compounds and methods | AR, NR5A1, PGR | AR 1/4885LMNA 2745/4885ALDH1A1 2131/4885 |
| US-20050288350-A1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer; 6-(bis-2,2,2-Trifluoroethyl)amino-4-trifluoromethylcoumarin | FSHR, CYP19A1, ESR2 | AR 9/4885LMNA 1047/4885ALDH1A1 2798/4885 |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | AR, NR5A1, PGR | AR 1/4885LMNA 2745/4885ALDH1A1 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.